Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus MYCOBUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus MYCOBUTIN.
ARIKAYCE KIT vs MYCOBUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Category C
Category C
Antimycobacterial
Antimycobacterial